maribavir
Selected indexed studies
- Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. (Clin Infect Dis, 2022) [PMID:34864943]
- Maribavir. (, 2012) [PMID:36469656]
- Maribavir. (Hosp Pharm, 2023) [PMID:37360201]
_Worker-drafted node — pending editorial review._
Connections
maribavir is a side effect of
Sources
- Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir. (2024) pubmed
- Current Perspectives on Letermovir and Maribavir for the Management of Cytomegalovirus Infection in Solid Organ Transplant Recipients. (2024) pubmed
- Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. (2022) pubmed
- Maribavir. (2012) pubmed
- Maribavir. (2023) pubmed
- Maribavir: Mechanism of action, clinical, and translational science. (2024) pubmed
- Maribavir: First Approval. (2022) pubmed
- Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (2024) pubmed
- New Perspectives on Antimicrobial Agents: Maribavir. (2022) pubmed
- Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection. (2025) pubmed